Drug Trial Radar · NCT06465329
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
Dec 4, 2029
Study completion Dec 27, 2034
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion. The aim of the resectable NSCLC portion is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. For each investigational arm, the available data will be reviewed to decide whether safety testing with chemotherapy is needed before moving the treatment combination to the main resectable NSCLC portion of the study. If safety testing with chemotherapy is required, adult participants whose tumour has spread to other organs or cannot be removed by surgery, will be enrolled in the unresectable/metastatic NSCLC portion of the study called the "safety lead-in." The aim of the unresectable/metastatic NSCLC safety lead-in portion is to evaluate the safety of the combination of Cemiplimab, chemotherapy, and an additional drug in participants with unresectable or metastatic NSCLC. For the resectable NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed * How much of the study drug(s) are in the blood at a given time * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects) For the unresectable/metastatic NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the additional drug in combination with cemiplimab and chemotherapy * How does the additional drug work in combination with cemiplimab and chemotherapy
Conditions
- Non Small Cell Lung Cancer
- NSCLC
Interventions
CemiplimabDrug
Administered per the protocol
Platinum-based chemotherapyDrug
Administered per the protocol
MarlotamigDrug
Administered per the protocol
REGN10597Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR)Time frame: Up to 12 weeks
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 9 weeks
- Occurrence of TEAEs leading to deathTime frame: Up to 9 weeks
- Occurrence of TEAEs leading to treatment discontinuationTime frame: Up to 9 weeks
- Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 9 weeks
- Occurrence of grade ≥3 laboratory abnormalitiesTime frame: Up to 9 weeks
- Number of participants unable to receive cemiplimab and chemotherapy for 2 consecutive cycles due to REGN10597-related toxicities during the first 3 cyclesTime frame: Up to 9 weeks
Locations
47 sites in 6 countries. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Orchard Healthcare Research Inc.
Skokie, Illinois
Karmanos Cancer Institute
Detroit, Michigan
Detroit Clinical Research Center
Farmington Hills, Michigan
Oncology Hematology Care Clinical Trials LLC
Cincinnati, Ohio
Providence Portland Medical Center
Portland, Oregon
University Of Nebraska Medical Center
Portland, Oregon
Lifespan Cancer Institute
Providence, Rhode Island
Prairie Lakes Healthcare System
Watertown, South Dakota
University of Tennessee Medical Center
Knoxville, Tennessee
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, Tennessee
BRCC/Oncology & Hematology Associates of SW Virginia
Blacksburg, Virginia
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil
Oncology Clinical Research Center
Cachoeiro de Itapemirim, Espírito Santo, Brazil
Instituto Mario Penna
Belo Horizonte, Minas Gerais, Brazil
Instituto Sul Mineiro De Oncologia LTDA
Pouso Alegre, Minas Gerais, Brazil
Instituto de Medicina Integral Professor Fernando Figueira
Recife, Pernambuco, Brazil
Liga Norte Riograndense Contra o Cancer
Natal, Rio Grande do Norte, Brazil
Hospital Mae de Deus Integrated Oncology Center
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Ynova Pesquisa Clinica
Florianópolis, Santa Catarina, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Unimed Sorocaba
Sorocaba, São Paulo, Brazil
Centre Hospitalier de la Cote Basque
Bayonne, France
Clinique Belharra
Bayonne, France
CHU Grenoble Alpes
Grenoble, France
Montpellier Academic Hospital
Montpellier, France
CHU Rennes
Rennes, Brittany Region, France
Institut Curie
Paris, Île-de-France Region, France
Centre Hospitalier Intercommunal Toulon - CHITS
Toulon, Var, France
University Hospital RWTH Aachen
Aachen, Germany
Klinikum Kassel GmbH, Hauttumorzentrum
Kassel, Hesse, Germany
University Medicine Gottingen
Göttingen, Lower Saxony, Germany
University of Leipzig
Leipzig, Saxony, Germany
MD Anderson Cancer Center
Madrid, Spain
Hospital Universitario Clinico San Carlos
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Virgen del Rocio
Seville, Spain
Hospital Clinico Universitario Valencia
Valencia, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.